-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3312 The Association Between Performance Status and Health-Related Quality of Life

Health Services and Outcomes Research – Malignant Diseases
Program: Oral and Poster Abstracts
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Sunday, December 6, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Mark A Fiala, BS, CCRP*, Jesse Keller, MD, Michael Slade, BA*, Keith Stockerl-Goldstein, MD, Michael Tomasson, MD, Ravi Vij, MD, MBA and Tanya M Wildes, MD, MSCI

Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

Background: Performance Status (PS) is often used to assess the functional status of cancer patients. One of the most commonly used scales is the Eastern Cooperative Oncology Group (ECOG) PS. Using the ECOG PS scale, the oncologist assigns a score ranging from 0 (Fully active, able to carry on all pre-disease performance without restriction) to 4 (completely disabled; cannot carry on any selfcare; totally confined to bed or chair). In multiple myeloma (MM), a PS > 2 has been associated with a 35% increased risk of death following autologous stem cell transplant (ASCT) (Turesson et al, Br J Haematol, 1999), and therefore a PS ≤ 2 is generally required for ASCT and for eligibility in clinical trials. 

PS is often seen as a surrogate for health-related quality of life (HRQOL), which are patient reported measure(s) of well-being; however, they are separate constructs. While poorer PS has been associated with a decrease in HRQOL, it is unclear how much of the variance in HRQOL is explained by PS.  

Objectives: 1) To determine the association between PS and HRQOL; 2) to determine how much variance in HRQOL is explained by PS.

Methods: Data was extracted from the open-access Multiple Myeloma Research Foundation (MMRF) Researcher Gateway corresponding with interim analysis 6 from the CoMMpass study. The CoMMpass study dataset included 562 patients who completed the EORTC QLQ-C30 and EORTC QLQ-MY20 at MM diagnosis. The range of scores for these HRQOL measures is 0-100, with higher scores indicating higher values. Data was analyzed using SPSS 21. The association between PS and HRQOL was assessed by one-way ANOVA tests; the amount of variance in HRQOL explained by PS was assessed by linear regression modeling.

Results: PS was associated with all 9 HRQOL scales analyzed (p<0.001). Poorer PS was associated with poorer global health, physical function, emotional functioning, cognitive functioning, social functioning, and role functioning; and greater disease symptoms, fatigue, and pain. However, PS explained only a portion of the variance seen with each scale. The most variance explained by PS was seen in the physical functioning scale (38%); the least was in the cognitive functioning scale (10%). Adding age and International Staging System (ISS) stage significantly improved 4 of the 9 models (physical functioning, emotional functioning, fatigue, and pain); however, improvements were modest (2-5%).    

Conclusions: PS was significantly associated with HRQOL but it was not considered a good explanatory model for any of the scales analyzed as it could not explain at least 50% of the variance, even after the addition of age and ISS stage. A broader examination of the patients' disease, functional, social, and socioeconomic context is needed to better understand HRQOL and to identify areas which may be improved by intervention.

Table 1: Association between Performance Status and Health-Related Quality of Life

Performance Status

0

n= 202

Performance Status

1

 n = 249

Performance Status

2

n = 47

Performance Status

 3/4

n = 29

p

Global Health Scale

75

54

33

21

<0.001

Physical Functioning Scale

93

73

33

13

<0.001

Cognitive Functioning Scale

100

83

83

66

<0.001

Emotional Functioning Scale

83

75

66

41

<0.001

Social Functioning Scale

100

66

33

33

<0.001

Role Functioning Scale

100

66

0

0

<0.001

Disease Symptom Scale

16

27

50

53

<0.001

Fatigue Scale

22

33

66

77

<0.001

Pain Scale

16

33

83

100

<0.001

  Table 2: Amount of Variance in Health-Related Quality of Life Explained by Performance Status, Age, and Stage

 

Model 1A

Model 2B

R2

F

p

R2

F change

pC

Global Health Scale

0.233

35.7

<0.001

0.234

1.6

0.188

Physical Functioning Scale

0.381

72.0

<0.001

0.405

6.3

<0.001

Cognitive Functioning Scale

0.105

13.8

<0.001

0.121

1.3

0.259

Emotional Functioning Scale

0.102

13.3

<0.001

0.158

10.1

<0.001

Social Functioning Scale

0.215

32.1

<0.001

0.222

2.1

0.106

Role Functioning Scale

0.295

48.7

<0.001

0.297

0.7

0.563

Disease Symptom Scale

0.148

19.9

<0.001

0.164

1.9

0.132

Fatigue Scale

0.235

35.9

<0.001

0.259

5.9

0.001

Pain Scale

0.204

30.0

<0.001

0.218

2.7

0.048

A-    Performance status

B-    Performance status, age, and International Staging System stage

C-    Of F change

 

Disclosures: Vij: Takeda, Onyx: Research Funding ; Celgene, Onyx, Takeda, Novartis, BMS, Sanofi, Janssen, Merck: Consultancy .

*signifies non-member of ASH